No items found.
X Fact
January 18, 2021
40 Second Read
Complexity Rating

Motivated Conjugates

By administering B12-drug conjugates, bound to IF, it is a strong hypothesis therefore, that it will deliver the drug to cells/tissues/organs that express cubilin. For example, by injecting a B12-PET imaging probe you would likely see sequestration in the kidneys. An extension on this idea has recently been shown utilizing IF produced in the plant by Xeragenx. Due to changes in the glycosylation pattens between Human IF produced endogenously and human IF produced in the plant, IF-B12-PET probe sequesters cleanly and clearly to the liver - a process likely mediated by a sugar receptor CD206. Targeting CD206 is an exciting current area of drug development, given its tie to inflammatory response.

Words You May Not Know
No items found.
Who Wrote This X Fact
Robert P. Doyle PhD
Bio Quick View

Prof. Robert Doyle is a medicinal chemist with an interest in pharmaceutical drug and probe development for the study and treatment of obesity and type 2 diabetes. He has a broad background in peptide and protein design and expression, synthetic bio-conjugate chemistry, drug delivery, protein biochemistry and assay development. In 2005, he was appointed Assistant Professor of Chemistry at Syracuse University and promoted, with tenure, to Associate Professor in 2009 and then full Professor in 2014. He is also adjunct Associate Professor of Medicine at SUNY, Upstate Medical University (UMU). In 2016, He was named the Laura J. and L. Douglas Meredith Professor, Syracuse University.  As a Principal Investigator (PI), he has focused on the  chemistry of vitamin B12 and its dietary pathway and components to modify drug pharmacodynamics and/or pharmacokinetics. He has been funded by the NIH and DoD, as well as multiple societies, foundations and pharmaceutical companies.  He has published over 100 research papers (35+ in the vitamin B12 space) and is the holder of over a dozen patents.

Top Picks
Recent X Facts